VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Relapse after HSCT 2021 | The use of DLI to prevent relapse

Christoph Schmid, MD, University of Augsburg, Augsburg, Germany, comments on the use of donor lymphocyte infusion (DLI) in relapse management. Dr Schmid reports that results from the PRO-DLI Phase II prospective trial (NCT02856464), assessing whether prophylactic donor DLI improves the disease-free survival of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), are eagerly awaited. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

Disclosures

Christoph Schmid, MD, has received research and travel grants from Novartis, Roche, Abbvie and Neovii; honoraria and speakers bureau from Novartis, Roche, BMS and Eurocept; and is also on the advisory boards of Novartis, Daichii, Eurocept and Roche.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter